First National Bank of South Miami Lowers Stock Position in Eli Lilly and Company (NYSE:LLY)

First National Bank of South Miami lowered its position in Eli Lilly and Company (NYSE:LLY) by 11.2% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,895 shares of the company’s stock after selling 240 shares during the period. First National Bank of South Miami’s holdings in Eli Lilly and Company were worth $889,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Oxler Private Wealth LLC increased its holdings in Eli Lilly and Company by 0.4% during the first quarter. Oxler Private Wealth LLC now owns 6,050 shares of the company’s stock valued at $2,078,000 after buying an additional 24 shares during the period. Missouri Trust & Investment Co grew its stake in Eli Lilly and Company by 3.2% in the first quarter. Missouri Trust & Investment Co now owns 774 shares of the company’s stock valued at $266,000 after purchasing an additional 24 shares during the last quarter. Silvercrest Asset Management Group LLC grew its stake in Eli Lilly and Company by 0.6% in the first quarter. Silvercrest Asset Management Group LLC now owns 4,331 shares of the company’s stock valued at $1,487,000 after purchasing an additional 25 shares during the last quarter. Cora Capital Advisors LLC grew its stake in Eli Lilly and Company by 2.8% in the first quarter. Cora Capital Advisors LLC now owns 956 shares of the company’s stock valued at $328,000 after purchasing an additional 26 shares during the last quarter. Finally, Sittner & Nelson LLC grew its stake in Eli Lilly and Company by 2.7% in the first quarter. Sittner & Nelson LLC now owns 1,003 shares of the company’s stock valued at $344,000 after purchasing an additional 26 shares during the last quarter. Hedge funds and other institutional investors own 81.38% of the company’s stock.

Insider Activity at Eli Lilly and Company

In related news, EVP Alonzo Weems sold 1,148 shares of Eli Lilly and Company stock in a transaction that occurred on Tuesday, September 12th. The shares were sold at an average price of $590.98, for a total value of $678,445.04. Following the completion of the sale, the executive vice president now owns 7,760 shares in the company, valued at approximately $4,586,004.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Eli Lilly and Company news, EVP Alonzo Weems sold 1,148 shares of Eli Lilly and Company stock in a transaction dated Tuesday, September 12th. The stock was sold at an average price of $590.98, for a total value of $678,445.04. Following the completion of the transaction, the executive vice president now directly owns 7,760 shares of the company’s stock, valued at approximately $4,586,004.80. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CAO Donald A. Zakrowski sold 600 shares of Eli Lilly and Company stock in a transaction dated Monday, August 21st. The shares were sold at an average price of $546.51, for a total value of $327,906.00. Following the completion of the transaction, the chief accounting officer now directly owns 5,378 shares of the company’s stock, valued at $2,939,130.78. The disclosure for this sale can be found here. In the last quarter, insiders sold 976,153 shares of company stock worth $21,080,192,113. Insiders own 0.13% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have issued reports on LLY. Credit Suisse Group lifted their target price on Eli Lilly and Company from $490.00 to $580.00 and gave the company an “outperform” rating in a research note on Wednesday, August 9th. Bank of America increased their price objective on Eli Lilly and Company from $500.00 to $600.00 in a report on Wednesday, August 9th. 22nd Century Group restated a “maintains” rating on shares of Eli Lilly and Company in a research note on Tuesday, June 27th. Cantor Fitzgerald reissued an “overweight” rating and issued a $630.00 price target on shares of Eli Lilly and Company in a report on Tuesday, September 5th. Finally, StockNews.com initiated coverage on Eli Lilly and Company in a research note on Thursday, August 17th. They set a “buy” rating on the stock. One investment analyst has rated the stock with a sell rating, one has given a hold rating and twenty have given a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $532.78.

Eli Lilly and Company Price Performance

NYSE:LLY opened at $571.17 on Tuesday. Eli Lilly and Company has a one year low of $296.32 and a one year high of $601.84. The company has a debt-to-equity ratio of 1.63, a quick ratio of 0.87 and a current ratio of 1.13. The stock has a market cap of $542.21 billion, a PE ratio of 79.44, a P/E/G ratio of 2.37 and a beta of 0.32. The stock has a 50 day moving average price of $512.56 and a 200 day moving average price of $439.28.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Tuesday, August 8th. The company reported $2.11 EPS for the quarter, beating analysts’ consensus estimates of $1.98 by $0.13. The company had revenue of $8.31 billion for the quarter, compared to the consensus estimate of $7.58 billion. Eli Lilly and Company had a return on equity of 65.00% and a net margin of 22.01%. The company’s revenue for the quarter was up 28.1% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.25 earnings per share. Equities research analysts expect that Eli Lilly and Company will post 9.84 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, September 8th. Investors of record on Tuesday, August 15th were issued a $1.13 dividend. The ex-dividend date was Monday, August 14th. This represents a $4.52 annualized dividend and a yield of 0.79%. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 62.87%.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.